Sonya Erickson

Cooley advised Outpace Bio, a cell therapy company using unrivaled artificial intelligence-powered protein design to program immune cells for improved function inside patients battling solid tumors, on its $144 million oversubscribed Series B financing.

Cooley advised Parse Biosciences on its $50 million Series C financing. Partner Sonya Erickson led the Cooley team advising Parse Biosciences, which develops single-cell sequencing products used by more than 1,000 labs worldwide.

Read more

Cooley advised CERo Therapeutics, an immunotherapy company, on its merger agreement with Phoenix Biotech Acquisition Corp.

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.

Cooley advised Route, a post-purchase experience platform and package tracking company, on its $200 million Series B financing round, which brings its valuation to $1.25 billion. Lawyers Dave Young, Joseph Kaczorowski, Robert Pollak and Roslyn Akel led the Cooley team advising Route.